Many risk factors for cardiovascular diseases have been identified, and cerebrovascular diseases share some of them. [1] [2] [3] [4] [5] Recent studies also indicated that several factors were associated with increased risk of cerebral infarction, 4,6-8 but few reports were concerned about their coeffects on patients with acute cerebral infarction (ACI). In this study, we explored the relationship between 21 plasma markers (16 for coagulation or anticoagulation, 4 for blood lipids, and 1 for fasting plasma glucose) and patients with ACI. We also assessed the contribution of other factors, such as hypertension, smoking, diabetes, alcohol use, and obesity.
Several studies have indicated association between hematologic markers and increased risks of cerebrovascular disease, but few reports referred to their roles together. We studied plasma levels of 16 hematologic markers in 50 cases diagnosed as acute cerebral infarction (ACI) and
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Materials and Methods

Cases
Between July 2005 and June 2006, 95 patients with suspected ACI were admitted to Union Hospital, Wuhan, China. All had (or would have) a computed tomography scan or magnetic resonance imaging on the first (or second) day of hospitalization. Of 95 patients, 63 patients were confirmed as having an ACI, but only 50 patients were included in the study. (We excluded 13 patients from the study: 4 for sampling failure, 6 for disagreement with blood sampling for different reasons [2 for age ≥80 years, 2 for poor mental status, 1 for fear of drawing blood, and 1 for emotional instability], and 3 for insufficiency of the blood sample.) All patients included in the study fulfilled the following criteria: (1) clinical symptoms and signs suggesting acute stroke, (2) magnetic resonance imaging or computed tomography scan indicated infarct instead of brain hemorrhage or occupying lesion, (3) from Chinese Han population and unrelated, and (4) a duration from onset of ACI symptoms to blood sampling of 48 hours or less. Patients with a previous cerebrovascular history were eligible.
Control Subjects
Control subjects (n = 54) were recruited from patients hospitalized in the Department of Otorhinolaryngology during the same period. None had any of the following conditions within 3 months before admission: surgery, trauma, fracture, malignancy, hematologic disorder, acute infection, organ dysfunction, or use of drugs or comorbidities (such as epistaxis, nasopharyngeal carcinoma, and sudden deafness) known to have great effects on the coagulation and anticoagulation systems. Control subjects with a history of stroke or venous thromboembolism were excluded.
Data Collection and Risk Factor Definition
Information about demographic characteristics and risk factors was collected in a case report form. Hypertension was defined as a history of receiving antihypertensive agents or a systolic blood pressure of 140 mm Hg or more and/or a diastolic blood pressure of 90 mm Hg or more on repeated measurements within a few days. Diabetes was considered when the fasting plasma glucose (FPG) level was 126 mg/dL (7.0 mmol/L) or more, a random blood glucose level was 200 mg/dL (11.1 mmol/L) or more with relevant symptoms, a 2-hour plasma glucose oral glucose tolerance test result was 200 mg/dL (11.1mmol/L) or more, and/or the patient was using glucose-lowering agents. Status of smoking and alcohol use was coded as none or current use. Presence of obesity was considered when the body mass index was 30 kg/m 2 or more for men and 28.6 kg/m 2 or more for women.
Blood Samples
Every blood sample was drawn from a fasting subject early in the morning of the second day during hospitalization in 2 Vacutainer tubes, one with 3.2% sodium citrate (anticoagulant/blood ratio, 9:1, Gongdong, Taizhou, China) and the other with separation gel (Becton Dickinson, Franklin Lakes, NJ). The former was centrifuged within 30 to 60 minutes at 2,500g for 6 minutes at room temperature, and plasma was subdivided and frozen at -80°C until analysis. The latter was quickly sent to the Department of Laboratory Medicine and analyzed for blood lipid and FPG levels in an automatic biochemical analyzer (Hitachi 7170A, Tokyo, Japan).
Reagents for Assay
Enzyme-linked immunosorbent assay kits for protein C (PC), free protein S, and total protein S were purchased from HYPHEN BioMed, Andrésy, France; kits for thrombomodulin and activated factor VII from American Diagnostica, Greenwich, CT; kits for factor VII antigen, tissue-type plasminogen activator, plasminogen activator inhibitor-1, and activity of tissue factor (aTF) from AssayPro, Winfield, MO; kits for P selectin from GeneMay, San Diego, CA; kits for fibrinogen, D dimer, activated partial thromboplastin time, and prothrombin time from Dade Behring, Marburg, Germany; kits for activated protein C (APC) ratio were purchased from Chromogenix, Milan, Italy; and kits for thrombin time were from the Biochemical Drug Plant of Special Economic Zone, Zhuhai, China. All markers were detected according to the corresponding instructions with the reagents, and all analysts had no information about the samples grouping until results were calculated.
The Union Hospital Ethics Committee approved the study protocol, and all participants gave their oral informed consent. This study was completed as a retrospective casecontrol study with a limited sample size.
Statistical Analysis
Continuous data are presented as mean (SD) or median (interquartile range). Differences between groups were analyzed by an unpaired samples t test for quantitative variables with normal distribution, the Mann-Whitney U test for quantitative variables with skewed distribution, and the χ 2 test for qualitative variables. Covariates with a P value of .05 or less in univariate analysis were included in a multivariate logistic regression analysis to assess risk factors for ACI. Statistical testing was conducted at a 2-tailed α level of .05. The data were analyzed by using the SPSS software package (version 13.0 for Windows, SPSS, Chicago, IL).
Results
The baseline characteristics of all subjects are given in ❚Table 1❚. There was significant difference in prevalence of hypertension between case and control groups (68% vs 2%; P < .001), but no significant differences were found in age, sex ratio, and prevalence of diabetes, smoking, alcohol use, and obesity in the 2 groups (all P values > .1).
Plasma levels of coagulation and anticoagulation parameters, FPG, and blood lipids in the 2 groups are given in ❚Table 2❚. Levels of thrombomodulin, aTF, and fibrinogen in cases were significantly higher than in controls (P < .001, P < .05, and P < .01, respectively). The APC ratio and concentration of high-density lipoprotein cholesterol (HDL-C) were significantly lower in cases compared with controls (P < .001 and P < .01, respectively). No significant differences were found in the levels of PC, free protein S, total protein S, activated factor VII, factor VII antigen, P selectin, tissue-type plasminogen activator, plasminogen activator inhibitor-1, FPG, low-density lipoprotein cholesterol, total cholesterol, triglycerides, prothrombin time, activated partial thromboplastin time, thrombin time, or D dimer between the 2 groups.
According to multivariate analysis ❚Table 3❚, hypertension, thrombomodulin, fibrinogen, aTF, and the APC ratio had significant associations with ACI (P < .001, P < .05, P < .05, P < .05, and P < .01, respectively).
We also compared the general characteristics and hematologic markers in patients with ACI who had a history of stroke with patients who did not. Age and plasma concentration of fibrinogen were higher in patients with a history of stroke (P = .029 and P = .032, respectively). The plasma level of PC was lower in patients with a history of stroke (P = .01). There were no significant differences in the prevalence of hypertension, diabetes, smoking, alcohol use, and obesity in the 2 subgroups (all P > .5) ❚Table 4❚. There were also no significant differences in the remaining hematologic markers and blood lipids (data not shown).
Discussion
Earlier studies had confirmed that hypertension was one of the most important risk factors for cerebrovascular disease. 1,9 A recent study also indicated that hypertension was the most prevalent (87.5%) risk factor followed by ischemic heart disease (35%) and diabetes. 10 Hypertension is strongly associated with atheromatous deposits blocking or narrowing brain arteries, predisposing to local clot formation. Atheroma and its ischemic consequences may damage cerebral arterioles and the brain tissue they supply. 11 Results of a large cohort study indicated that improvement of hypertension control might be responsible for a steady decline in incidence of lacunar infarction in a Japanese population. 5 Our findings also showed that hypertension contributed to the development of acute cerebral infarction ( Thrombomodulin is an integral membrane-bound glycoprotein, predominantly expressed at the surface of vascular endothelial cells. 12 As a cofactor for thrombin-mediated cleavage of PC at the N-terminus, 13 it amplifies the event of activation of PC more than 1,000-fold. It is also a cofactor for thrombinmediated activation of the thrombin-activatable fibrinolysis inhibitor. 14 In this study, we detected the concentrations of soluble thrombomodulin (sTM) in plasma and found that the levels in cases were significantly higher than in controls (Table  2) . Previous studies also indicated that increased sTM levels had been associated with recurrent myocardial and cerebral infarction. 6, 15 Univariate and multivariate analyses indicated that sTM was a risk factor with a lower 95% CI bound of the OR of more than 1.0 (Table 3 ), but no relationship was found between high levels of sTM and recurrent cerebral infarction in our study (data not shown). This may partly be attributed to our small sample. Several studies have shown that increased concentration of sTM was associated with reduced risk not only for cerebral infarction but also for coronary heart disease. 6, 16, 17 Our results were contrary to these findings. A cross-sectional study also found that circulating levels of thrombomodulin were elevated in hypertensive patients compared with normotensive subjects. 18 We considered the effect of hypertension status on levels of thrombomodulin in our cases. Patients with ACI with hypertension (n = 34) had higher levels of thrombomodulin than patients without hypertension (n = 16), but a significant difference was not found (4.91 ± 1.92 vs 4.11 ± 1.42 ng/mL; P > .05). So, it is unconvincing to consider the discrepancy to be caused by a high prevalence of hypertension in our study cases. However, a different duration from onset of ACI symptoms to blood sampling in studies may affect plasma levels of thrombomodulin and could partly account for the disparity between the findings of our study and others. Also, different races of the population studied may have a certain role in this disparity.
Fibrinogen is involved in primary hemostasis, platelet aggregation, and leukocyte-endothelial cell interactions and is the major determinant of whole blood and plasma viscosity. [19] [20] [21] Elevated levels of fibrinogen are associated with cardiovascular and cerebrovascular events. 3, [22] [23] [24] A recent study also showed that an increased concentration of plasma fibrinogen was an independent predictor of 1-year case fatality for acute ischemic stroke (P = .013; OR, 1.69). 25 Plasma levels of fibrinogen were significantly higher in hypertensive diabetics than in normotensive diabetics. 26 In the present study, levels of plasma fibrinogen were higher in ACI cases than in controls (450 ± 160 vs 380 ± 90 mg/dL [4.5 ± 1.6 vs 3.8 ± 0.9 g/L]; P < .01). Univariate and multivariate analyses found a relationship between high plasma levels of fibrinogen and cerebral infarction (OR, 1.59; 95% CI, 1.12-2.25; and OR, 2.09; 95% CI, 1.02-4.27, respectively). Therefore, we can conclude that the plasma fibrinogen level is an independent risk factor for cerebral infarction.
Although the prevalence of hypertension in the ACI subgroups had no contrast, a significant difference was found in the plasma levels of fibrinogen between the 2 subgroups (Table 4) . Bivariate correlation analysis found no relationship between plasma fibrinogen levels and ages in patients with a history of stroke (P = .084; Spearman rank correlation coefficient = 0.543). So the difference of plasma levels of fibrinogen between the 2 subgroups may be mainly due to the contribution of a history of cerebral infarction rather than old age. 3 Tissue factor has a critical role in initiation of the coagulation cascade; it binds activated factor VII, resulting in activation of factor IX and factor X and ultimately leading to fibrin formation. Higher levels of tissue factor in plasma 27 have been found in patients with acute myocardial infarction and unstable angina than in patients with stable angina and control subjects. 28, 29 A recent study also indicated that plasma aTF and antigen were both significantly increased in acute myocardial infarction and acute ischemic stroke. 30 In the present study, levels of aTF were significantly higher in cases than in controls (193.42 ± 82.74 vs 163.71 ± 38.09 pg/mL; P < .05), but no significant difference was found in the ACI subgroups (data not shown). This finding implies that high activity of tissue factor in plasma has an important role in the development of cerebral infarction and can be regarded as a poor risk factor for ischemic stroke according to univariate and multivariate analyses (OR, 1.01; 95% CI, 1.001-1.014; and OR, 1.02; 95% CI, 1.001-1.030, respectively).
Several studies have confirmed that a low level of serum HDL-C was associated with an increased risk of cerebral infarction. 4, 31, 32 In our study, the levels of serum HDL-C were significantly lower in cases than in controls (42 ± 13 vs 49 ± 10 mg/dL [1.08 ± 0.34 vs 1.28 ± 0.26 mmol/L]; P < .01), and univariate analysis showed that HDL-C protected against acute cerebral infarction (OR, 0.07; 95% CI, 0.01-0.39), but multivariate regression analysis did not support that a low level of serum HDL-C was an independent risk factor for ACI (OR, 0.15; 95% CI, 0.02-1.55). Limited samples and a high prevalence of hypertension in the cases may account for this finding.
The APC ratio gives an overall estimation of the anticoagulant effect of APC and, thus, provides information on the thrombotic risk associated with inherited and acquired APC resistance. Interestingly, the APC ratio is not a simple, 1-variable reflection of the APC response in vivo. Instead, it seems to reflect an anticoagulant system response that may decrease under a hypercoagulable state. 33 van der Bom et al 34 showed that a low APC ratio was associated with an increased risk of stroke, independent of the factor V mutation. Our study also indicated that a decreased APC ratio was associated with increased risk of cerebral infarction according to univariate and multivariate analyses (OR, 0.01; 95% CI, 0.001-0.165; and OR, 0.01; 95% CI, 0.00-0.32, respectively), but no significant difference was found in the ACI subgroups in the present study. This finding needs to be ascertained in a larger casecontrol study.
There were no significant differences in other variables except mean age, protein C, and fibrinogen (Table 4) in the subgroups. Bivariate correlation analysis did not find a relationship between any 2 of the 3 parameters (data not shown). Naturally, small samples could not verify this finding.
To explain the aberrations in thrombomodulin, fibrinogen, aTF, HDL-C, and APC ratio between cases and controls, we divided ACI cases into 2 subgroups by hypertension status: hypertensive ACI and normotensive ACI. By using the MannWhitney U test, we found no differences in thrombomodulin, fibrinogen, aTF, HDL-C, and APC ratio between subgroups ❚Table 5❚. So we can conclude that the aberrations in thrombomodulin, fibrinogen, aTF, HDL-C, and APC ratio between cases and controls in this study were associated with cerebral infarction rather than hypertension.
All together, our findings showed that hypertension and increased plasma levels of thrombomodulin, fibrinogen, and aTF were independently poor indicators for patients with ACI. Hypotensive and fibrinolytic drugs may prevent the development of ACI. Studies with larger samples are needed to further confirm our findings and investigate other risk factors for acute ischemic stroke.
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